• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

尿嘧啶衍生物/熊果酸杂合物——作为抗癌剂的天然衍生化合物。

Uracil derivatives/ursolic acid hybrids - naturally derived compounds as anticancer agents.

作者信息

Michalak Olga, Cybulski Marcin, Kubiszewski Marek, Finiuk Nataliya, Kozak Yuliia, Milenkovic Dejan, Żurawicka Sylwia, Roszczenko Piotr, Bielawska Anna, Trzaskowski Bartosz, Gornowicz Agnieszka

机构信息

Chemistry Section; Pharmacy, Cosmetic Chemistry and Biotechnology Research Group, Łukasiewicz Research Network-Industrial Chemistry Institute, 8 Rydygiera Str, Warsaw, 01-793, Poland.

Analytical Research Section, Pharmaceutical Analysis Laboratory, Łukasiewicz Research Network-Industrial Chemistry Institute, 8 Rydygiera Str, Warsaw, 01-793, Poland.

出版信息

Sci Rep. 2025 Aug 6;15(1):28803. doi: 10.1038/s41598-025-14351-y.

DOI:10.1038/s41598-025-14351-y
PMID:40770022
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12329029/
Abstract

A series of new uracil derivatives/ursolic acid hybrids were designed and synthesised as potential cytotoxic agents. The uracil, thymine, 6-methyluracil and 2-thiouracil moieties were linked to ursolic acid (1) through alkyl chains of different lengths (either four or six -CH- units). The cytotoxic activity of the synthesised conjugates was determined using the hormone-dependent breast cancer cell line MCF-7, the triple-negative breast cancer (TNBC) cell line MDA-MB-231 and normal cell lines: human skin fibroblasts (CCD-25Sk) and human bronchial epithelium (BEAS-2B). The five compounds, 4a, 5a, 6a, 7a and 9a, exhibited a significant reduction in the cell viability of human BC cell lines. Analog 6a, which demonstrated high cytotoxic activity against MCF-7 and MDA-MB-231 cell lines with IC values of 14.00 µM and 5.83 µM, respectively, was also antitumorigenic in all biochemical assays. It increased p53 and Bax levels in MDA-MB-231 cells as well as significantly decreased Akt kinase levels in the tested cells, and effectively inhibited collagen biosynthesis. Finally, for the selected compounds, we computationally predicted their ADME properties and performed molecular docking to Akt protein kinase. The results of computational docking indicated that the preferred binding mode for all of them was the inactive form of Akt kinase, as in the case with known Akt allosteric inhibitors.

摘要

设计并合成了一系列新型尿嘧啶衍生物/熊果酸杂化物作为潜在的细胞毒性剂。尿嘧啶、胸腺嘧啶、6-甲基尿嘧啶和2-硫尿嘧啶部分通过不同长度的烷基链(四个或六个-CH-单元)与熊果酸(1)相连。使用激素依赖性乳腺癌细胞系MCF-7、三阴性乳腺癌(TNBC)细胞系MDA-MB-231以及正常细胞系:人皮肤成纤维细胞(CCD-25Sk)和人支气管上皮细胞(BEAS-2B)测定合成缀合物的细胞毒性活性。化合物4a、5a、6a、7a和9a对人乳腺癌细胞系的细胞活力有显著降低。类似物6a对MCF-7和MDA-MB-231细胞系表现出高细胞毒性活性,IC值分别为14.00 μM和5.83 μM,在所有生化测定中也具有抗肿瘤作用。它增加了MDA-MB-231细胞中p53和Bax的水平,同时显著降低了测试细胞中Akt激酶的水平,并有效抑制了胶原蛋白的生物合成。最后,对于选定的化合物,我们通过计算预测了它们的ADME性质,并对Akt蛋白激酶进行了分子对接。计算对接结果表明,与已知的Akt变构抑制剂情况一样,它们所有的优选结合模式都是Akt激酶的无活性形式。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43d9/12329029/94a1d523e5f8/41598_2025_14351_Fig15_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43d9/12329029/3806d558daa9/41598_2025_14351_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43d9/12329029/c448810cd890/41598_2025_14351_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43d9/12329029/e2b535d658b9/41598_2025_14351_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43d9/12329029/1cc10131a3e2/41598_2025_14351_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43d9/12329029/4c7f83ec08df/41598_2025_14351_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43d9/12329029/5e1ace4fb042/41598_2025_14351_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43d9/12329029/8d8b669fb83e/41598_2025_14351_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43d9/12329029/1e265fd8f39d/41598_2025_14351_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43d9/12329029/c2a63c737d90/41598_2025_14351_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43d9/12329029/f02adc5be291/41598_2025_14351_Fig10_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43d9/12329029/a00b2a1f406f/41598_2025_14351_Fig11_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43d9/12329029/34484b6b1583/41598_2025_14351_Fig12_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43d9/12329029/58119b481b5e/41598_2025_14351_Fig13_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43d9/12329029/fc135c437853/41598_2025_14351_Fig14_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43d9/12329029/94a1d523e5f8/41598_2025_14351_Fig15_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43d9/12329029/3806d558daa9/41598_2025_14351_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43d9/12329029/c448810cd890/41598_2025_14351_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43d9/12329029/e2b535d658b9/41598_2025_14351_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43d9/12329029/1cc10131a3e2/41598_2025_14351_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43d9/12329029/4c7f83ec08df/41598_2025_14351_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43d9/12329029/5e1ace4fb042/41598_2025_14351_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43d9/12329029/8d8b669fb83e/41598_2025_14351_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43d9/12329029/1e265fd8f39d/41598_2025_14351_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43d9/12329029/c2a63c737d90/41598_2025_14351_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43d9/12329029/f02adc5be291/41598_2025_14351_Fig10_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43d9/12329029/a00b2a1f406f/41598_2025_14351_Fig11_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43d9/12329029/34484b6b1583/41598_2025_14351_Fig12_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43d9/12329029/58119b481b5e/41598_2025_14351_Fig13_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43d9/12329029/fc135c437853/41598_2025_14351_Fig14_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43d9/12329029/94a1d523e5f8/41598_2025_14351_Fig15_HTML.jpg

相似文献

1
Uracil derivatives/ursolic acid hybrids - naturally derived compounds as anticancer agents.尿嘧啶衍生物/熊果酸杂合物——作为抗癌剂的天然衍生化合物。
Sci Rep. 2025 Aug 6;15(1):28803. doi: 10.1038/s41598-025-14351-y.
2
Novel benzenesulfonamides as dual VEGFR2/FGFR1 inhibitors targeting breast cancer: Design, synthesis, anticancer activity and in silico studies.新型苯磺酰胺类双重 VEGFR2/FGFR1 抑制剂靶向治疗乳腺癌:设计、合成、抗癌活性及计算机模拟研究。
Bioorg Chem. 2024 Nov;152:107728. doi: 10.1016/j.bioorg.2024.107728. Epub 2024 Aug 17.
3
Synthesis and apoptotic induction of sulfonamide-based chalcone hybrids as first-in-class dual histone deacetylase‑carbonic anhydrase inhibitors with potential anti-tubulin activity.基于磺胺的查耳酮杂化物的合成及其凋亡诱导作用,作为具有潜在抗微管蛋白活性的一流双组蛋白脱乙酰酶-碳酸酐酶抑制剂。
Bioorg Chem. 2025 Jun 20;163:108694. doi: 10.1016/j.bioorg.2025.108694.
4
Novel indole Schiff base β-diiminato compound as an anti-cancer agent against triple-negative breast cancer: In vitro anticancer activity evaluation and in vivo acute toxicity study.新型吲哚席夫碱β-二亚胺化合物作为一种针对三阴性乳腺癌的抗癌剂:体外抗癌活性评价和体内急性毒性研究。
Bioorg Chem. 2024 Nov;152:107730. doi: 10.1016/j.bioorg.2024.107730. Epub 2024 Aug 16.
5
Synthesis of S-alkylated oxadiazole bearing imidazo[2,1-b]thiazole derivatives targeting breast cancer: In vitro cytotoxic evaluation and in vivo radioactive tracing studies.靶向乳腺癌的含咪唑并[2,1-b]噻唑衍生物的S-烷基化恶二唑的合成:体外细胞毒性评估和体内放射性示踪研究。
Bioorg Chem. 2024 Dec;153:107935. doi: 10.1016/j.bioorg.2024.107935. Epub 2024 Nov 2.
6
Efficient Synthesis, Anticancer Evaluation of Triazole-Thiadiazole/Benzo[d]Oxazole Scaffolds, and Investigation of Their Reactivity Properties Using Density-Functional Theory Calculations and In Silico Docking.三唑-噻二唑/苯并[d]恶唑支架的高效合成、抗癌评估及其反应性质的密度泛函理论计算和计算机对接研究
Chem Biodivers. 2025 Feb 19:e202402470. doi: 10.1002/cbdv.202402470.
7
Novel quinazolin-4-one based derivatives bearing 1,2,3-triazole and glycoside moieties as potential cytotoxic agents through dual EGFR and VEGFR-2 inhibitory activity.新型喹唑啉-4-酮类衍生物,含有 1,2,3-三唑和糖苷片段,具有双重 EGFR 和 VEGFR-2 抑制活性,有望成为细胞毒性药物。
Sci Rep. 2024 Oct 23;14(1):24980. doi: 10.1038/s41598-024-73171-8.
8
Development of novel quinazolinone-based compounds with anti-proliferative activity as dual STAT-3 and c-Src inhibitors: design, synthesis and molecular dynamic studies.新型喹唑啉酮类化合物作为双靶点STAT-3和c-Src抑制剂的抗增殖活性研究:设计、合成及分子动力学研究
Bioorg Chem. 2025 Aug;163:108753. doi: 10.1016/j.bioorg.2025.108753. Epub 2025 Jul 15.
9
Design of chiral 2-oxazoline-based amino acid bioConjugates as anticancer agents: Synthesis, in vitro anticancer activity, ADMET prediction with molecular docking and molecular dynamic simulation insights.基于手性2-恶唑啉的氨基酸生物共轭物作为抗癌剂的设计:合成、体外抗癌活性、基于分子对接和分子动力学模拟的ADMET预测
Arch Biochem Biophys. 2025 Sep;771:110507. doi: 10.1016/j.abb.2025.110507. Epub 2025 Jun 13.
10
Ursolic acid affects autophagy and apoptosis of breast cancer through PLK1 via AKT/mTOR signaling pathway.熊果酸通过PLK1经由AKT/mTOR信号通路影响乳腺癌的自噬和凋亡。
Med Oncol. 2025 Jul 21;42(8):358. doi: 10.1007/s12032-025-02917-9.

本文引用的文献

1
An Update on Pentacyclic Triterpenoids Ursolic and Oleanolic Acids and Related Derivatives as Anticancer Candidates.五环三萜类化合物熊果酸和齐墩果酸及其相关衍生物作为抗癌候选物的最新进展
Antioxidants (Basel). 2024 Aug 6;13(8):952. doi: 10.3390/antiox13080952.
2
ProTox 3.0: a webserver for the prediction of toxicity of chemicals.ProTox 3.0:一个用于预测化学品毒性的网络服务器。
Nucleic Acids Res. 2024 Jul 5;52(W1):W513-W520. doi: 10.1093/nar/gkae303.
3
Akt Inhibitor Advancements: From Capivasertib Approval to Covalent-Allosteric Promises.
Akt 抑制剂的进展:从卡培他滨的批准到共价变构的承诺。
J Med Chem. 2024 Apr 25;67(8):6052-6063. doi: 10.1021/acs.jmedchem.4c00075. Epub 2024 Apr 9.
4
Shaping the future of antiviral Treatment: Spotlight on Nucleobase-Containing drugs and their revolutionary impact.塑造抗病毒治疗的未来:关注含核苷药物及其革命性影响。
Bioorg Chem. 2024 Mar;144:107150. doi: 10.1016/j.bioorg.2024.107150. Epub 2024 Jan 27.
5
Proline metabolism shapes the tumor microenvironment: from collagen deposition to immune evasion.脯氨酸代谢塑造肿瘤微环境:从胶原沉积到免疫逃逸。
Curr Opin Biotechnol. 2023 Dec;84:103011. doi: 10.1016/j.copbio.2023.103011. Epub 2023 Oct 20.
6
Pyrroline-5-carboxylate reductase 1 reprograms proline metabolism to drive breast cancer stemness under psychological stress.吡咯啉-5-羧酸还原酶 1 通过重新编程脯氨酸代谢在心理应激下驱动乳腺癌干性。
Cell Death Dis. 2023 Oct 16;14(10):682. doi: 10.1038/s41419-023-06200-5.
7
Synthesis, Biological Activity, ADME and Molecular Docking Studies of Novel Ursolic Acid Derivatives as Potent Anticancer Agents.新型熊果酸衍生物的合成、生物活性、ADME 和分子对接研究及其作为潜在抗癌药物的应用。
Int J Mol Sci. 2023 May 17;24(10):8875. doi: 10.3390/ijms24108875.
8
Rule of five violations among the FDA-approved small molecule protein kinase inhibitors.FDA 批准的小分子蛋白激酶抑制剂的五规则违反情况。
Pharmacol Res. 2023 May;191:106774. doi: 10.1016/j.phrs.2023.106774. Epub 2023 Apr 17.
9
Apoptotic proteins with non-apoptotic activity: expression and function in cancer.具有非凋亡活性的凋亡蛋白:在癌症中的表达和功能。
Apoptosis. 2023 Jun;28(5-6):730-753. doi: 10.1007/s10495-023-01835-3. Epub 2023 Apr 4.
10
Strategies for Efficient Targeting of Tumor Collagen for Cancer Therapy.癌症治疗中高效靶向肿瘤胶原蛋白的策略。
Cancers (Basel). 2022 Sep 27;14(19):4706. doi: 10.3390/cancers14194706.